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ABSTRACT 
Novel Approaches to Breast Cancer Therapy: Evaluation of Next Generation 
Dendrimers for Drug Delivery. (April 2010) 
 
Merideth Snow 
Department of Nutrition and Food Science 
Texas A&M University 
 
Research Advisor: Dr. Clinton Allred 
Department of Nutrition and Food Science 
 
 
 
Breast cancer is the second leading cause of cancer deaths in women with approximately 
40,000 patient deaths each year. Theranostics is an emerging area of cancer research in 
which chemically synthesized molecules are used to simultaneously deliver a diagnostic 
factor (e.g. DNA) and chemotherapeutic drug. This can be accomplished through the use 
of a dendrimer-based vector system that is capable of delivering DNA and a 
chemotherapeutic agent to the cancer cells. A previous study from our laboratory has 
shown that treating the cancer cells with a novel dendrimer construct (G2-NH2) alone, 
without drug or DNA present, can be cytotoxic. The purpose of this study was to test the 
next generation of dendrimers for the ability to deliver DNA into cancer cells and their 
efficacy to induce cell death. MCF-7 cells were transfected with green fluorescent 
protein (GFP) plasmid DNA using dried or liquid forms of the second generation 
dendrimers (F2-1 and G2-5). Following transfection, fluorescence was measured to 
assess the transfection capability of the dendrimers. Dried forms of the dendrimers 
showed very little fluorescence while liquid forms of both dendrimers revealed low-level 
fluorescence. The transfection experiment was repeated for an additional set of 
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dendrimers (M6-24, M8-96, F4-2, F4-1, and F2-1). Dendrimer F4-2 showed the highest 
transfection efficiency. Additionally, cytotoxicity of the second generation dendrimers 
was measured.  Dendrimers M8-96, M6-24, and F4-2 were cytotoxic at high 
concentrations while dendrimers F4-1 and F2-1 were not. The dendrimer compounds 
may represent the future of breast cancer therapy. 
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CHAPTER I 
INTRODUCION 
Breast cancer is the second most commonly diagnosed malignancy among women. In 
2008, more than 180,000 new cases were identified in the United States and an estimated 
41,000 women died of the disease (1). Approximately 70% of primary breast cancers 
express estrogen receptor alpha (ERα) (2). In such cases, anti-estrogen therapy is a 
commonly used treatment approach. Although this therapy has proven effective in initial 
stages of treatment, tumors begin to show resistance due to ERα unresponsiveness after 
prolonged exposure to the drugs. Therefore, in order to successfully utilize anti-estrogen 
therapy, it is critical to know whether ERα is still active in the tumor as treatment 
progresses. 
 
Furthermore, gene therapy in which genetic material is introduced in cells for therapeutic 
purposes is being explored as a potential method of cancer treatment (3). One specific 
area of study focuses on the use of non-viral, dendrimer- based vector systems to deliver 
DNA to various cell lines. Although the DNA-dendrimer complex has reduced 
transfection efficiency as compared to viral vectors, the potential for genetic 
recombination, toxicity, and immunogenicity is lessened with its use (4).  
 
 
___________ 
This thesis follows the style of Cancer Research. 
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Additionally, it has been shown that dendrimers have the capacity to be derivatized with 
a range of drugs, including those used for chemotherapy, in which form they act as drug 
transporters (5). Camptothecin is a chemotherapeutic agent often used in the treatment of 
late stage breast cancer and has shown the ability to link to a dendrimer, forming a drug-
dendrimer complex. It has also been demonstrated that the dendrimer will then deliver 
camptothecin to the targeted tumor cells, at which point it is released (6). 
 
The future goal of research in this area called “theranostics”, focuses on the ability of the 
dendrimer-based vector system to diagnose ERα responsiveness in breast cancer cells 
while simultaneously delivering a chemotherapeutic drug. The purpose of such a 
combination is twofold. First, the delivery of the drug serves to destroy cancer cells. In 
the process, the DNA in the dendrimer-based vector system can provide information as 
to whether the cells express ERα. With this information, it can be determined if anti-
estrogen therapy is an effective method of treatment. 
 
This study begins to explore the potential use of dendrimers in the treatment of breast 
cancer by testing the ability of the experimental compounds to deliver fluorescent 
reporter DNA constructs to the cancer cells.    
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CHAPTER II 
MATERIALS AND METHODS
Cells 
MCF 7 cells purchased from ATCC were used in this study. MCF 7 cells are human 
breast carcinoma cells that were isolated in 1970 from a 69 year old woman (7). The 
cells were maintained in phenol red free DMEM containing 10% FBS at 37ºC in a 5% 
CO2 atmosphere.  
 
GFP plasmid 
Isolated GFP plasmid was added to E. coli DH5alpha. The combination was placed on 
ice for 30 minutes, then placed at 42ºC for 45 seconds, and then placed back on ice for 2 
minutes. After this process, the competent bacteria had taken up the GFP plasmid. The 
plasmid was then purified using the Quiagen Plasmid Plus Midi Kit. 
 
The purification of the plasmid through this process began by adding an alkaline lysate 
to the pelleted bacteria. The lysate was then cleared through centrifugation. After 
washing, the DNA was collected in the elute and precipitated with isopropanol. The 
result of this process is ultrapure GFP plasmid DNA. 
 
General methods for transfection 
MCF 7 cells were plated on a 96-well plate in concentrations of 30,000 cells per well. 
Cells incubated at 37ºC in a 5% CO2 atmosphere for 24 hours. 
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Following the incubation period, all wells were treated with a form of the transfection 
mixture containing OptiMEM, 1.5µg of DNA and a varying dendrimer concentration. 
The transfection mixture was removed from the cells after a period of 4-6 hours and 
replaced with 100µL of media. After a period of 18 hours, media was removed. The 
wells were then washed twice with 50µL PBS. 100µL PBS were added and the plate was 
then assessed for total fluorescing units using a plate reader. Following the read, 
fluorescence was examined under the microscope. 
 
Positive and negative control wells were made using the transfection reagent 
Lipofectamine 2000 as the positive control. Lipofectamine, OptiMEM, and DNA were 
combined in a 1.5mL tube, allowed to incubate at room temperature for 20 minutes, and 
added to the positive control wells. OptiMEM and DNA were combined, allowed to 
incubate at room temperature for 20 minutes, and added to the negative control wells. 
 
Modification to general transfection methods 
 
First generation dendrimers 
In this set of experiments, cells were treated with either dried or liquid dendrimer. 
Treatment of wells with dried dendrimer was as follows: two dendrimers (F2-1 and G2-
5) of varying concentrations (n/p 5, n/p 7.5, n/p 10) were dried in a separate plate. 
OptiMEM and DNA were added to each well of the dried dendrimer plate and gently 
mixed. The plate was allowed to gently rock at room temperature throughout a 20 
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minute incubation period. After this period, the mixtures were added to the 
corresponding wells on the 96-well plate according to the appropriate dendrimer 
concentrations. 
 
Two liquid dendrimers (also F2-1 and G2-5) of varying concentrations (n/p 5, n/p 7.5, 
n/p 10) were combined with OptiMEM and the DNA and allowed to incubate at room 
temperature for 20 minutes. After the incubation period, the mixtures were added to the 
corresponding wells according to the appropriate dendrimer concentrations. 
 
Next generation dendrimers 
In this set of experiments, OptiMEM, 1.5µg DNA, and varying concentrations (n/p 5, 
n/p 7.5, n/p 10) of one of five liquid dendrimers (M6-24, M8-24, F4-1, F4-2, F2-1) were 
combined and allowed to incubate for 20 minutes. After this period, the mixtures were 
added to the appropriate wells according to dendrimer type and concentration. The plates 
were incubated for 4-6 hours before the transfection mixture was removed. Following 
another 18 hour incubation period, the plates were analyzed via the plate reader and the 
microscope.  
 
Dendrimer cytotoxicity 
In a series of cytotoxicity experiments, 10,000 cells per well were plated on a 96-well 
plate and allowed to incubate for a period of 24 hours. Following this period, cells were 
treated with varying concentrations of the second generation dendrimers.  
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In the experiment, the negative control wells were treated with a media and water 
combination. Blank wells were treated with media only. The all dead control wells were 
treated with 30µL of TritonX-100. 
 
Following treatment, the cells incubated at 37⁰C for 72 hours. After this period, 15µL of 
Promega G4000 MTT Dye assay were added to the cells and allowed to incubate for 4 
more hours. 100µL of a stop solution were then added and the cells incubated for 1 more 
hour. Following this incubation, the cells were read with a plate reader at the absorbance 
of 570nm with a reference wavelength of 650nm.   
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CHAPTER III 
 
RESULTS 
 
First generation dendrimer transfection 
Figure 1 represents a series of preliminary experiments illustrating the transfection 
capabilities of the first generation of dendrimers used (n/p 7.5). Lipofectamine showed 
optimal transfection as a positive control, producing 50% higher fluorescence than the 
negative control. When viewed under the microscope, the positive control was 
characterized by intense, green fluorescence.  
 
The liquid dendrimers expressed higher levels of fluorescence than the dried dendrimers. 
Liquid dendrimer F2-1 showed 73% higher fluorescence than the negative control while 
liquid dendrimer G2-5 showed 66% higher fluorescence than the negative control. Both 
liquid dendrimers F2-1 and G2-5 expressed higher fluorescence than the positive control 
as well. However, when examined under the microscope, low-level fluorescence at an 
intensity much less than the positive control was observed. 
 
Dried dendrimer F2-1 showed fluorescence 5% greater than that of the negative control 
while dried dendrimer G2-5 produced fluorescence 3% greater than that of the negative 
control. Under the microscope, little to no fluorescence was visible. 
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Figure 1: First generation dendrimer transfection- n/p 7.5. 30,000 cells / well were 
plated. Lipofectamine was used as the positive control. Following a 24 hour incubation 
period, cells were treated with a transfection mixture consisting of OptiMEM, 1.5µg 
GFP, and varying concentrations of dried or liquid dendrimers. After a 4-6 hour 
incubation period, the transfection mixture was removed and replaced with media. Plates 
were read for total fluorescing units after another 18 hour incubation period. Fig. 1 
represents the transfection efficiency of the positive control and the dendrimers as 
compared to the negative control. 
 
Second generation dendrimer transfection 
Figures 2 represents a comparison of the transfection capabilities of the next generation 
of liquid dendrimers, M6-24, M8-96, F4-1, and F4-2 as well as dendrimer  
F2-1 from the first generation at three different concentrations: n/p 5, n/p 7.5, and n/p 10. 
Lipofectamine functioned as an optimal positive control, exceeding the fluorescence of 
the negative control by 50%. Lipofectamine again showed an intense, green fluorescence 
under the microscope while each of the dendrimers produced a very low-level 
fluorescence under the microscope. 
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Dendrimer concentration n/p 5 
Liquid dendrimers M8-96 and F4-2 showed the highest transfection efficiencies with 
fluorescence at 56% and 57% higher than the negative control respectively. Each of 
these liquid dendrimers exceeded the fluorescence of the positive control as well. (Figure 
2, Part A) 
 
Dendrimer concentration n/p 7.5  
Liquid dendrimer F4-2 again showed the highest transfection efficiency. F4-2 
fluorescence was 74% higher than the negative control and exceeded the fluorescence of 
the positive control. (Figure 2, Part B) 
 
Dendrimer concentration n/p 10 
Liquid dendrimers M8-96, F4-1, and F4-2 showed the highest transfection efficiencies 
showing 121%, 104%, and 114% higher fluorescence than the negative control 
respectively. All three of these dendrimers also showed more fluorescence than the 
positive control. (Figure 2, Part C) 
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A: Second generation dendrimer transfection- n/p 5. 
 
Figure 2: Second generation dendrimer transfection. 30,000 cells / well were plated. 
Lipofectamine was used as the positive control. Following a 24 hour incubation period, 
cells were treated with a transfection mixture consisting of OptiMEM, 1.5µg GFP, and 
liquid dendrimers at concentrations of either n/p 5, n/p 7.5, and n/p 10. After a 4-6 hour 
incubation period, the transfection mixture was removed and replaced with media. Plates 
were read for total fluorescing units after another 18 hour incubation period. Fig. 2 
represents the transfection efficiency of the positive control and the dendrimers as 
compared to the negative control. 
 
 
 
 
 
11 
 
B: Second generation dendrimer transfection- n/p 7.5. 
 
 
 
 
 C: Second generation dendrimer transfection- n/p 10. 
 
 
Figure 2 continued 
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Second generation dendrimer cytotoxicity 
Liquid dendrimers M8-96, M6-24, and F4-2 showed cytotoxicity at high concentrations. 
Specifically, dendrimer M8-96 was cytotoxic at concentration 62.2nM, M6-24 at 133nM 
and 266nM, and F4-2 at 134nM. The remaining dendrimers, F4-1 and F2-1, were not 
cytotoxic at any of the tested concentrations. (Figure 3) 
 
 
 
 
A: Second generation dendrimer cytotoxicity- M8-96 
 
 
Figure 3: Second generation dendrimer cytotoxicity. MCF-7 cells were grown at 37⁰C. 
10,000 cells / well were plated on a 96-well plate and incubated for 24 hours. Following 
this period, cells were treated with varying concentrations of the second generation 
dendrimers. Negative control wells were treated with a media and water combination. 
Blank wells were treated with media only. The all dead positive control wells were 
treated with 30µL of TritonX-100. Following treatment, the cells incubated at 37⁰C for 
72 hours. T15µL of Promega G4000 MTT Dye assay then were added to the cells and 
allowed to incubate for 4 hours. 100µL of a stop solution were then added and the cells 
incubated for 1 hour. Cells were read with a plate reader at the absorbance of 570nm 
with a reference wavelength of 650nm. Data are represented according to absorbance. 
Lower absorbance indicates greater cell death. 
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 B: Second generation dendrimer cytotoxicity- M6-24 
 
 
 
 
C: Second generation dendrimer cytotoxicity- F4-2. 
 
 
Figure 3 continued 
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CHAPTER IV 
CONCLUSIONS 
An emerging area of breast cancer research focuses on using non-viral, dendrimer-based 
vector systems to deliver DNA and chemotherapeutic drugs to cancer cells. The purpose 
of such a system would be to provide drug therapy to destroy cancer cells while also 
gaining knowledge of the responsiveness of ERα within the remaining cancer cells using 
a reporter DNA. 
 
The purpose of this study was two-fold. The first goal was to evaluate the ability of two 
generations of dendrimers to deliver DNA through transfection experiments. The next 
goal was to determine the cytotoxic abilities of the same dendrimers.  
 
First generation dendrimer transfection 
In the initial set of experiments, dried and liquid dendrimers were used. Using dried 
dendrimer in a transfection experiment is a relatively new idea and this was the first 
experiment to gauge its transfection efficiency. Given the data obtained in this study, 
dendrimer transfection of MCF-7 cells appears to be more effective when liquid 
dendrimer is used rather than dried dendrimer. For this reason, liquid dendrimer was 
solely used for the remaining experiments of the study. 
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Second generation dendrimer transfection 
In the following set of experiments, the transfection efficiency of a new generation of 
dendrimers was observed. Transfection of the second generation dendrimers revealed 
that liquid dendrimer F4-2 has the highest transfection efficiency at all concentrations 
tested. Additionally, liquid dendrimers M8-96 and F4-1 showed strong transfection 
efficiencies at higher dendrimer concentrations.  
 
Second generation dendrimer cytotoxicity 
A previous study from our laboratory showed the cytotoxic capability of dendrimer G2-
NH2 when used to treat MCF-7 cells (5). Therefore, it was of interest to determine the 
cytotoxic capabilities of this generation of dendrimers as well. This set of experiments 
revealed that liquid dendrimers M8-96, M6-24, and F4-2 are cytotoxic to MCF-7 cells at 
high concentrations while dendrimers F4-1 and F2-1 are not cytotoxic at the 
concentrations tested. Consequently, dendrimers M8-96, M6-24, and F4-2 are cytotoxic 
even without being derivatized to a chemotherapeutic drug. 
 
Summary 
Dendrimer- DNA- drug constructs may represent the future of breast cancer therapy. 
This study investigated the ability of the next generations of dendrimers to deliver 
reporter DNA to MCF-7 cells as well as the cytotoxic capabilities of the dendrimers. 
Future studies should focus on the relationship between cytotoxic dendrimers and 
chemotherapeutic drug transport. 
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